Rigel Pharmaceuticals Reports Strong First Quarter Financial Results for 2026
Rigel Pharmaceuticals Reports Strong First Quarter Financial Results for 2026
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a biotechnology company focused on hematologic disorders and cancer, reported its financial results for the first quarter of 2026, showing notable revenue growth and profitability.
Financial Highlights
In the first quarter of 2026, Rigel reported total revenues of $58.8 million. This includes net product sales of $54.9 million and $3.9 million in contract revenues from collaborations. Compared to the same period in 2025, net product sales rose by an impressive 26%. The company's net income for the quarter was reported at $8.7 million, demonstrating a solid profitability level. This growth is attributed to Rigel's successful management and strategic focus on its expanding commercial portfolio, which includes key products such as TAVALISSE®, GAVRETO®, and REZLIDHIA®.
Product Performance
- - TAVALISSE: Generated net product sales of $37.3 million, marking a 31% increase compared to the previous year.
- - GAVRETO: Saw a 7% growth, with net sales reaching $9.6 million.
- - REZLIDHIA: Achieved net sales of $8.0 million, a rise of 31%.
These results indicate not only the effectiveness of Rigel's marketing strategies but also the increasing demand for its therapies among patients suffering from various conditions.
Clinical Developments
Rigel is progressing with its Phase 1b clinical study evaluating R289, a promising candidate for treating patients with lower-risk myelodysplastic syndromes (MDS). The company is on track to complete the dose expansion phase of the study and anticipates selecting the recommended Phase 2 dose in the second half of 2026. Additionally, preliminary data from this study is expected to be shared by the end of 2026, further validating Rigel's commitment to innovation and patient care.
Corporate Updates
Rigel has made significant corporate moves in early 2026, including the restructuring of its credit relationship with MidCap Financial. The new revolving credit facility of $40 million, with the option to increase to $60 million, provides the company with flexibility in funding its development plans. On the governance front, Rigel appointed Michael P. Miller to its Board of Directors, expanding its leadership team.
However, the company announced the upcoming termination of its collaboration agreement with Eli Lilly and Company regarding the development of ocadusertib, which will take effect on June 15, 2026. Despite these challenges, Rigel is well-positioned financially, with a cash balance that supports its ongoing clinical projects.
Market Outlook
For the entirety of 2026, Rigel has reaffirmed its revenue guidance of approximately $275 to $290 million. This positive outlook is supported by anticipated net product sales of around $255 to $265 million and contract revenues of approximately $20 to $25 million. Rigel continues to expect positive net income throughout the year as it funds both existing and new projects within its development portfolio.
Upcoming Events
Rigel is holding a live conference call and webcast today to discuss these financial results in detail. Investors and stakeholders can participate in the call at 4:30 PM Eastern Time. The event will offer insights into the company's future activities and strategic initiatives.
Conclusion
Rigel Pharmaceuticals has successfully navigated the first quarter of 2026, showcasing impressive financial results and a strategic outlook for growth. With a robust product lineup and forward-looking clinical developments, Rigel is positioned for continued success in the competitive biotech landscape.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.